Integra LifeSciences returns founder-era CEO Stuart Essig to top role
Integra LifeSciences Holdings has named Stuart Essig, the company's board chairman, as president and chief executive officer with effect from 1 May 2026. Essig succeeds Mojdeh Poul, who is described in the announcement as "pursuing other opportunities." The board was explicit that the appointment is permanent and that no external CEO search will be initiated.
The move represents a significant return to the helm for Essig, who previously led Integra as both president and CEO from 1997 through to 2012, a period that saw the company grow into a recognised global medical technology player in neurosurgery and tissue reconstruction. He has remained close to operations in his subsequent role as executive chairman, which the company says involved direct engagement with operational and quality priorities over the past two years. In addition to the CEO appointment, he retains his chairmanship of the board — a dual role that consolidates authority at the top of the organisation.
Commercial restructuring
Alongside the CEO transition, Integra has created a new chief commercial officer role and appointed Michael McBreen to fill it. McBreen previously served as executive vice president and president of the Codman Specialty Surgical division. In the new position, both of Integra's divisions and the full global commercial structure will report to him — a significant elevation of the commercial function and a signal that revenue performance is a near-term priority. The company says the restructuring is intended to sharpen customer and market-facing execution.
Essig's own statement pointed to a "clear mandate" from the board around operational discipline, commercial focus, and quality and compliance — areas that have featured prominently in Integra's recent investor communications following a period of restructuring.
Market context and read-across
The leadership change arrives at a sensitive moment for Integra. The NASDAQ-listed group, which competes in neurosurgery, tissue reconstruction, and specialised surgical solutions, has been navigating quality remediation work and a business-process transformation programme that were initiated under Poul's tenure. Essig acknowledged those efforts in his statement, crediting Poul with progress on portfolio prioritisation and operational resilience, while signalling that the pace of execution would accelerate under his stewardship.
In the broader medical devices landscape, leadership continuity and operational credibility are closely watched by institutional investors, particularly where FDA quality-system requirements intersect with commercial performance. Integra's decision to appoint an insider with three decades of company knowledge, rather than recruit externally, suggests the board is prioritising stability and speed of execution over a strategic pivot. Peers in the surgical instruments and neurotechnology space — including larger players such as Stryker and Medtronic — have in recent years faced similar pressure to balance quality-system investment with top-line growth, and Integra's restructured commercial reporting line mirrors a broader sector trend toward elevating commercial leadership to the C-suite.
Essig is expected to address the transition and the company's first-quarter 2026 financial results on a conference call that took place on the morning of the announcement. Investors will be watching for any guidance revision or commentary on the timeline for completing the ongoing quality remediation and business-transformation work.